Skip to main content
Erschienen in: Diabetologia 6/2019

26.02.2019 | Article

Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use

verfasst von: Louis Potier, Ronan Roussel, Gilberto Velho, Pierre-Jean Saulnier, Anisoara Bumbu, Odette Matar, Fabrice Schneider, Stéphanie Ragot, Michel Marre, Kamel Mohammedi, Samy Hadjadj

Erschienen in: Diabetologia | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Recently, safety data signalled an increased risk of amputations in people taking canagliflozin, a sodium−glucose cotransporter 2 (SGLT2) inhibitor. If this side effect is due to drug-induced hypovolaemia, diuretics should also increase that risk. The aim of this study was to analyse the association between diuretic use and the risk of lower limb events (LLEs) in people with type 2 diabetes.

Methods

SURDIAGENE (SUivi Rénal, DIAbète de type 2 et GENEtique) is a prospective observational cohort that includes people with type 2 diabetes enrolled from 2002 to 2012 and followed-up until onset of LLE, death or 31 December 2015, whichever came first. Primary outcome was the first occurrence of LLE, a composite of lower limb amputation (LLA) and lower limb revascularisation (LLR). The rates of primary outcome were compared between participants taking and not taking diuretics at baseline in a Cox-adjusted model.

Results

At baseline, of the 1459 participants included, 670 were taking diuretics. In participants with and without diuretics, the mean ages were 67.1 and 62.9 years and 55.8% and 59.8% were men, respectively. During a median follow-up of 7.1 years, the incidence of LLE was 1.80 per 100 patient-years in diuretic users vs 1.00 in non-users (p < 0.001). The HR for LLE in users vs non-users was 2.08 (95% CI 1.49, 2.93), p < 0.001. This association remained significant in a multivariable-adjusted model (1.49 [1.01, 2.19]; p = 0.04) and similar after considering death as a competing risk (subhazard ratio 1.89 [1.35, 2.64]; p < 0.001). When separated, LLA but not LLR, was associated with the use of diuretics: 2.01 (1.14, 3.54), p = 0.02 and 1.05 (0.67, 1.64), p = 0.84, respectively, in the multivariable-adjusted model.

Conclusions/interpretation

Among people with type 2 diabetes treated with diuretics, there was a significant increase in the risk of LLE, predominantly in the risk of LLA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
7.
9.
Zurück zum Zitat Hadjadj S, Fumeron F, Roussel R et al (2008) Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care 31(9):1847–1852. https://doi.org/10.2337/dc07-2079 CrossRefPubMedPubMedCentral Hadjadj S, Fumeron F, Roussel R et al (2008) Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care 31(9):1847–1852. https://​doi.​org/​10.​2337/​dc07-2079 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981–2997. https://doi.org/10.1001/jama.288.23.2981 CrossRef ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981–2997. https://​doi.​org/​10.​1001/​jama.​288.​23.​2981 CrossRef
15.
Zurück zum Zitat Brown MJ, Palmer CR, Castaigne A et al (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356(9227):366–372. https://doi.org/10.1016/S0140-6736(00)02527-7 CrossRefPubMed Brown MJ, Palmer CR, Castaigne A et al (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356(9227):366–372. https://​doi.​org/​10.​1016/​S0140-6736(00)02527-7 CrossRefPubMed
22.
26.
Zurück zum Zitat Ryan PB, Buse JB, Schuemie MJ et al (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20(11):2585–2597. https://doi.org/10.1111/dom.13424 CrossRefPubMedPubMedCentral Ryan PB, Buse JB, Schuemie MJ et al (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20(11):2585–2597. https://​doi.​org/​10.​1111/​dom.​13424 CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Ueda P, Svanstrom H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365CrossRefPubMedPubMedCentral Ueda P, Svanstrom H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365CrossRefPubMedPubMedCentral
Metadaten
Titel
Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use
verfasst von
Louis Potier
Ronan Roussel
Gilberto Velho
Pierre-Jean Saulnier
Anisoara Bumbu
Odette Matar
Fabrice Schneider
Stéphanie Ragot
Michel Marre
Kamel Mohammedi
Samy Hadjadj
Publikationsdatum
26.02.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 6/2019
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-4835-z

Weitere Artikel der Ausgabe 6/2019

Diabetologia 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.